Search

Physician-scientist Aimee Crago studies mechanisms by which common genomic events drive initiation and progression of soft tissue tumors.

… The rarity of soft tissue sarcomas has historically made the definition of genomic drivers of their initiation and progression difficult.  Through copy number, whole exome and transcriptome analyses, however, common events associated with these lesions have recently been defined.  The focus of our laboratory

The Osorio Lab studies the mechanisms of antibody-mediated immunity, with a focus on myeloid cell reprograming to advance cancer immunotherapies.

… The Osorio lab investigates the mechanisms underlying antibody-mediated immunity, and how we can leverage these insights to develop durable and effective antibody-based immunotherapies. Our research focuses on harnessing the untapped potential of the innate immune system – particularly the myeloid compartment

Physician-scientist Veronica Rotemberg studies imaging standards and artificial intelligence (AI) for dermatology applications.

… The Dermatology Imaging Informatics Group is focused on developing, benchmarking, and validating artificial intelligence (AI) tools for dermatologic applications, especially melanoma detection. We are interested in model development, human-AI interaction, and prospective validation of image classification

The Pillarsetty Laboratory develops bioactive radiopharmaceuticals and fluorophores for molecular characterization and targeted treatment of cancer.

… Targeted Theranostics Laboratory Molecularly targeted therapy modulates a dysregulated target(s) and/or biologic pathway(s) that provides survival advantage for cancer cells. This targeting enables achieve selective destruction of cancer cells while minimizing harm to normal cells. We work on the development

Cell biologist Xuejun Jiang studies programmed cell death, molecular mechanisms, and their roles in tumorigenesis.

… The research of my laboratory focuses on two directions highly relevant to cancer biology, (1) the molecular basis of programmed cell death processes (including apoptosis and ferroptosis), and their roles in human disease; and (2) the molecular basis of autophagy and its role in cancer. We also study

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.

… The goal of our research program is to understand the detailed mechanisms by which a cancer cell can develop resistance to therapies targeting its oncogenic driver; and to exploit those findings to elucidate the biology of cancer and identify more effective treatments for cancer patients. The focus of

The Nikolov laboratory focuses on the structural, biophysical, and biochemical characterization of the molecular mechanisms of cell-cell interactions and signal transduction across the plasma membrane.

… Research in our laboratory aims to characterize the molecular mechanisms underlying cell-to-cell interactions and signal transduction across the cell membrane. We are particularly interested in understanding how receptors located on the surface of developing axons and neurons interact with extracellular

Physician-scientist Andrew Intlekofer investigates why cancer cells depend on specific pathways of nutrient metabolism.

… Andrew Intlekofer is an Assistant Member in the Human Oncology and Pathogenesis Program and an Attending Physician on the Lymphoma Service in the Department of Medicine. Dr. Intlekofer’s research investigates how deregulated metabolic pathways contribute to cancer development and how metabolic enzymes

Heeseon An’s lab studies protein degradation in health and disease using chemical, biological, and proteomics tools.

… The research in An lab centers around protein degradation processes in health and disease. We investigate protein degradation processes using chemical biology tools and unbiased proteomic approaches to discover previously unknown degradational pathways and molecular mechanisms. Specific research areas

Mechanisms of genetic and epigenetic cooperativity which drive myeloid transformation; Elucidating and modeling evolution from hematopoietic stem/progenitor cells to clonal hematopoiesis and then to myeloid malignancies; Identification and credentialing novel therapeutic dependencies in myeloid malignancies

… The goal of our research is to improve our understanding of the genetic basis of blood disorders known as myeloid malignancies, and to use this knowledge to improve therapies for patients with these disorders. Our efforts are focused on the identification and characterization of somatic mutations in